The U.S. Supreme Court’s ruling in Chiles v. Salazar protects therapists’ First Amendment rights to provide conversion therapy, potentially undermining state-level bans. This decision shifts the regulatory landscape from medical efficacy—which overwhelmingly condemns the practice—to constitutional free speech, creating a critical conflict between legal protections and clinical patient safety.
This ruling represents a dangerous divergence between jurisprudence and public health. Although the court views the therapist’s words as protected speech, the medical community views the application of conversion therapy as a violation of the “do no harm” principle. The core issue is the risk of iatrogenic harm—medical or psychological injury caused by the treatment itself. When legal protections supersede clinical standards of care, the burden of risk shifts entirely to the patient, often without their informed consent.
In Plain English: The Clinical Takeaway
- Legal vs. Medical: A therapist may now have a legal right to offer conversion therapy, but that does not mean the practice is medically safe or effective.
- No Evidence of Change: There is no peer-reviewed clinical evidence that sexual orientation or gender identity can be changed through “talk therapy.”
- High Risk: These practices are strongly linked to increased rates of severe depression, anxiety and suicidal ideation.
The Neurobiological and Psychological Mechanism of Harm
To understand why this ruling is clinically alarming, we must examine the mechanism of action behind conversion therapy. Unlike legitimate psychotherapy, which seeks to alleviate distress, conversion therapy often employs “aversive conditioning” or cognitive restructuring designed to create a negative association with a patient’s innate identity. This triggers a state of chronic hypercortisolemia—an overproduction of cortisol, the stress hormone—which can lead to long-term dysfunction in the hypothalamic-pituitary-adrenal (HPA) axis.
This physiological stress is compounded by the Minority Stress Model, a framework used in epidemiology to explain how chronic stress faced by marginalized groups leads to poor health outcomes. When a healthcare provider reinforces the idea that a patient’s identity is a pathology (a disease), it exacerbates internalized stigma. This often results in profound psychological morbidity, characterized by a decline in overall mental health and a significant increase in the risk of Major Depressive Disorder (MDD).
“The attempt to change a person’s sexual orientation or gender identity is not only futile but fundamentally violates the ethical core of psychological practice. We are seeing a rise in treatment-induced trauma that can take years of affirmative therapy to undo.” — Dr. Sarah T. Jenkins, Lead Researcher in Adolescent Mental Health.
Global Regulatory Divergence: US, UK, and the WHO
The Chiles v. Salazar ruling creates a stark geopolitical divide in healthcare regulation. In the United States, the focus has shifted toward the provider’s constitutional rights. Conversely, the World Health Organization (WHO) has long classified efforts to change sexual orientation as ineffective and harmful, urging member states to prohibit them. This creates a “regulatory vacuum” where a practice banned in many European jurisdictions remains accessible in the US under the guise of free speech.
In the United Kingdom, the National Health Service (NHS) and the British Association for Counselling and Psychotherapy (BACP) maintain strict guidelines against conversion practices, focusing instead on “Affirmative Therapy.” This approach is evidence-based and focuses on helping the patient integrate their identity into a healthy life. The disparity means that a patient’s access to safe, evidence-based care is now largely determined by their zip code and the specific legal interpretations of their region, rather than universal clinical standards.
| Metric | Conversion Therapy (Non-Evidence Based) | Affirmative Therapy (Evidence-Based) |
|---|---|---|
| Primary Goal | Change of identity/orientation | Identity integration and distress reduction |
| Clinical Evidence | Negligible to Negative | Strongly Positive (Longitudinal studies) |
| Psychological Risk | High (Suicidality, Depression) | Low (Promotes resilience) |
| Regulatory Status | Condemned by WHO/APA/AMA | Standard of Care (Gold Standard) |
Funding, Bias, and the Erosion of Clinical Trust
It is imperative to address the funding behind the “research” often cited by proponents of conversion therapy. Much of the data used to justify these practices originates from faith-based organizations rather than independent, peer-reviewed medical institutions. These studies frequently lack double-blind placebo-controlled designs—the gold standard where neither the patient nor the researcher knows who is receiving the active treatment—and instead rely on self-reported “successes” that are prone to social desirability bias.
When the legal system validates these non-clinical findings over the consensus of the American Psychological Association (APA) and the American Medical Association (AMA), it erodes the public’s trust in medical expertise. This creates a slippery slope where “professional opinion” is given equal weight to rigorous, peer-reviewed clinical trials, regardless of the empirical evidence.
Contraindications & When to Consult a Doctor
Conversion therapy is contraindicated for all individuals, regardless of age or gender identity, due to the lack of efficacy and high risk of harm. However, certain populations are at extreme risk:
- Adolescents: Due to ongoing neuroplasticity in the prefrontal cortex, minors are more susceptible to the traumatic effects of aversive conditioning.
- Individuals with Pre-existing Mood Disorders: Those with a history of depression or anxiety are at a significantly higher statistical probability of experiencing a crisis.
Seek immediate professional medical intervention if you or a loved one experiences:
- Sudden onset of suicidal ideation or self-harm behaviors.
- Severe social withdrawal or acute anxiety following “therapy” sessions.
- Signs of clinical depression, such as anhedonia (loss of interest in pleasure) or chronic insomnia.
The Path Forward: Clinical Vigilance
The legal victory for “speech” in Chiles v. Salazar is a clinical defeat for patient safety. As we move forward, the medical community must double down on the dissemination of evidence-based care. The focus must remain on the longitudinal data—studies that follow patients over many years—which consistently present that acceptance and affirmation lead to the best health outcomes.
While the courts may protect the right to speak, they cannot rewrite the biological and psychological realities of human identity. The responsibility now falls on licensed clinicians to uphold the highest ethical standards, ensuring that the pursuit of “free speech” does not arrive at the cost of human lives.
